Benitec Biopharma Inc. (BNTC) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
3940 Trust Way
Hayward, CA 94545
United States of America (the)
Phone
510 780 0819
Website
Sector
Healthcare
Industry
Biotechnology
Employees
19
First IPO Date
June 24, 2014
| Name | Title | Pay | Year Born |
| Jerel A. Banks | Executive Chairman & Chief Executive Officer | 1.07M | 1976 |
| Michael Graham | Head of Discovery & Founding Scientist | 139,665 | N/A |
| Megan Joan Boston | CFO & Secretary | 870,813 | 1973 |
| Sophie Mukadam | Chief Operating Officer | 940,439 | 1981 |
| Claudia Kloth | Senior Vice President of Manufacturing | 0 | N/A |
Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. Its Silence and Replace, a DNA-directedRNA interference platform combines RNA interference with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The company is developing BB-301, an AAV-based gene therapy designed to silence the expression of the disease-causing gene for the treatment of oculopharyngeal muscular dystrophy related dysphagia. Benitec Biopharma Inc. is headquartered in Hayward, California.